Ocuphire Announces Late Breaking Presentation On APX3330 ZETA-1 Clinical Data At American Diabetes Association Annual Conference
Portfolio Pulse from Happy Mohamed
Ocuphire Pharma announced that Dr. Victor H. Gonzalez will present late breaking clinical data on APX3330 ZETA-1 at the American Diabetes Association Annual Conference. The presentation will focus on the efficacy and safety results of the ZETA-1 Phase 2 trial in diabetic retinopathy.
June 21, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ocuphire Pharma's presentation of APX3330 ZETA-1 clinical data at the ADA Annual Conference may generate interest and potentially impact the stock price.
The presentation of positive clinical data on APX3330 ZETA-1 at a major conference like the American Diabetes Association Annual Conference can generate interest in Ocuphire Pharma and its stock. This may lead to increased demand for the stock and potentially impact its price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100